Document is current
Any future updates will be listed below
-
Authors
Park, Matthew D.
Yatim, Nader
Zhang, Jing
Cho, Byuri Angela https://orcid.org/0000-0002-1802-7709
Yoo, Seong-Keun
Schaefer, Maximilian M. https://orcid.org/0000-0002-6038-7847
Chowell, Diego
Puleston, Daniel J.
Merad, Miriam https://orcid.org/0000-0002-4481-7827
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA254104)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA154947)
U.S. Department of Defense (ME220130)
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA283469)
U.S. Department of Health & Human Services | National Institutes of Health (1DP2AI177905-0)
Damon Runyon Cancer Research Foundation (Rachleff Innovator Award)
Blavatnik Family Foundation
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 12 May 2025
First Online: 14 August 2025
Competing interests
: M.M. serves on the scientific advisory board of and holds stock from Compugen Inc., Dynavax Inc., Asher Bio Inc., Dren Bio Inc., Genenta Inc., Oncoresponse Inc., Myeloid Therapeutics Inc., DemBio Inc. and Owkin Inc. M.M. serves on the scientific advisory board for contracted research from Genentech Inc., Regeneron Inc. and Boehringer Ingelheim Inc. M.M. is listed as an inventor on a patent application (#16/092576) submitted by the Icahn School of Medicine at Mount Sinai that covers the use of multiplex immunohistochemistry to characterize tumors and treatment responses. The technology is filed through the Icahn School of Medicine at Mount Sinai and is currently unlicensed. The other authors declare no competing interests.
